finance.yahoo.comNov 14

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

Original reporting

finance.yahoo.com

Published Nov 14, 2026, 12:57 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 14, 2026, 1:10 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

HeartFlow: 3 Key Takeaways for Long-Term Investors — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

Med

Why it matters

The disclosed operational improvements and product launch could improve revenue visibility and investor sentiment.

Market read

Positive guidance and new product rollout may drive short‑term price appreciation for HLF.

What to watch

Potential regulatory hurdles for new software and adoption rates in hospitals.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

HeartFlow is a digital health company offering CT‑based coronary artery disease assessment tools.

Market effects

Sector

Strengthens the cardiovascular imaging software niche, may boost peers with similar tech.

Regional

U.S. healthcare tech sector could see modest gains.

Global

Limited to investors focused on med‑tech and digital health.

Counterpoint

What could challenge this read

Guidance to cash‑flow profitability by 2028 is long‑term; short‑term execution risk remains.

Key entities

Executive
Vikram Verghese
Chief Financial Officer providing financial commentary.
Executive
John Farquhar
President and CEO outlining product strategy.

Read at source ← All news

Med

Canaccord Genuity maintains HeartFlow at Buy, raises price target to $69 from $56

Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.

tradingview.comNov 13

High

Stifel maintains HeartFlow at Buy, raises price target to $70 from $45

Stifel upgraded its price target for HeartFlow to $70 from $45, a 55.6% increase, implying 16.8% upside from the Nov 12 close of $59.92. The firm maintained its Buy rating on the company.

tradingview.comNov 13

$HTFLMed

Stifel raises HeartFlow stock price target to $70 on strong growth

Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.

investing.comNov 13

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

finance.yahoo.comNov 13

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.